����

An antioxidant that targets specific cell structures—mitochondria—may be able to reverse some of the negative effects of aging on arteries, reducing the risk of heart disease, according to a new study by the University of Colorado Boulder.

When the research team gave old mice—the equivalent of 70- to 80-year-old humans—water containing an antioxidant known as MitoQ for four weeks, their arteries functioned as well as the arteries of mice with an equivalent human age of just 25 to 35 years.

The researchers believe that MitoQ affects the endothelium, a thin layer of cells that lines our blood vessels. One of the many functions of the endothelium is to help arteries dilate when necessary. As people age, the endothelium is less able to trigger dilation and this leads to a greater susceptibility to cardiovascular disease.

“One of the hallmarks of primary aging is endothelial dysfunction,” said Rachel Gioscia-Ryan, a doctoral student in С����-Boulder’s Department of Integrative Physiology and lead author of the new study. “MitoQ completely restored endothelial function in the old mice. They looked like young mice.”

The study, published in the Journal of Physiology, was funded by the National Institute on Aging, one of the 27 institutes and centers of the National Institutes of Health and a leader in the scientific effort to understand the nature of aging.

To trigger blood vessel dilation, the endothelium makes nitric oxide. As we age, the nitric oxide meant to cause dilation is increasingly destroyed by reactive oxygen species such as superoxide, which are produced by many components of our body’s own cells, including organelles called mitochondria.

In a double-whammy, superoxide also reacts directly with the enzyme that makes nitric oxide, reducing the amount of nitric oxide being produced to begin with. All of this means less blood vessel dilation.

Even in the young and healthy, mitochondria produce superoxide, which is necessary in low levels to maintain important cellular functions. Superoxide is kept in check by the body’s own antioxidants, which combine with superoxide to make it less reactive and prevent oxidative damage to cells.

“You have this kind of balance, but with aging there is this shift,” said Gioscia-Ryan, who works in Professor Douglas Seals’ Integrative Physiology of Aging Laboratory at С����-Boulder. “There become way more reactive oxygen species than your antioxidant defenses can handle.”

That phenomenon, known as oxidative stress, occurs when the cells of older adults begin to produce too much superoxide and other reactive oxygen species. Mitochondria are a major source of superoxide in aging cells. The increased superoxide not only interacts with nitric oxide and the endothelium, but can also attack the mitochondria themselves. The damaged mitochondria become increasingly dysfunctional, producing even more reactive oxygen species and creating an undesirable cycle.

Past studies have looked at whether taking antioxidant supplements long term could improve vascular function in patients with cardiovascular disease by restoring balance to the levels of superoxide, but they’ve largely shown that the strategy isn’t effective.

This new study differs because it uses an antioxidant that specifically targets mitochondria. Biochemists manufactured MitoQ by adding a molecule to ubiquinone (also known as coenzyme Q₁₀), a naturally occurring antioxidant. The additional molecule makes the ubiquinone become concentrated in mitochondria.

“The question is, ‘Why aren’t we all just taking a bunch of vitamin C?” Gioscia-Ryan said. “Scientists think that, taken orally, antioxidants like vitamin C aren’t getting to the places where the reactive oxygen species are being made. MitoQ basically tracks right to the mitochondria.”

The findings of the study indicate that the strategy of specifically targeting the mitochondria may be effective for improving the function of arteries as we age. In addition to improving endothelial function, the MitoQ treatment increased levels of nitric oxide, reduced oxidative stress and improved the health of the mitochondria in the arteries of old mice.��

Other С����-Boulder co-authors of the study include postdoctoral researchers Thomas LaRocca and Amy Sindler, professional research assistant Melanie Zigler and Seals. Professor Michael Murphy of the Medical Research Council’s Mitochondrial Biology Unit in Cambridge, England, who helped develop MitoQ, also is a co-author. MitoQ is manufactured by MitoQ Ltd., and is available as a dietary supplement and skin cream.

The study was supported by award number T32AG000279 from the National Institute on Aging. The content of the published study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contact:
Rachel Gioscia-Ryan, 303-492-3106
Rachel.Gioscia@colorado.edu
Laura Snider, ����-Boulder media relations, 303-735-0528
Laura.Snider@colorado.edu